Literature DB >> 15688042

Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.

Robert C Brunham1, José Rey-Ladino.   

Abstract

Sexually transmitted Chlamydia trachomatis infections are a serious public-health problem. With more than 90 million new cases occurring annually, C. trachomatis is the most common cause of bacterial sexually transmitted disease worldwide. Recent progress in elucidating the immunobiology of Chlamydia muridarum infection of mice has helped to guide the interpretation of immunological findings in studies of human C. trachomatis infection and has led to the development of a common model of immunity. In this review, we describe our current understanding of the immune response to infection with Chlamydia spp. and how this information is improving the prospects for development of a vaccine against infection with C. trachomatis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688042     DOI: 10.1038/nri1551

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  263 in total

1.  [Diagnosis and treatment of Chlamydia trachomatis infections].

Authors:  T Meyer
Journal:  Hautarzt       Date:  2012-01       Impact factor: 0.751

2.  Reductions in sexually transmitted infections associated with popular opinion leaders in China in a randomised controlled trial.

Authors:  Mary Jane Rotheram-Borus; Zunyou Wu; Li-Jung Liang; Li Li; Roger Detels; Jihui Guan; Yueping Yin; Dallas Swendeman
Journal:  Sex Transm Infect       Date:  2011-01-29       Impact factor: 3.519

3.  The glycolipid exoantigen derived from Chlamydia muridarum activates invariant natural killer T cells.

Authors:  Ying Peng; Lei Zhao; Sudhanshu Shekhar; Lu Liu; Hong Wang; Qiang Chen; Xiaoling Gao; Xi Yang; Weiming Zhao
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

4.  Identification of Chlamydia trachomatis outer membrane complex proteins by differential proteomics.

Authors:  Xiaoyun Liu; Mary Afrane; David E Clemmer; Guangming Zhong; David E Nelson
Journal:  J Bacteriol       Date:  2010-03-26       Impact factor: 3.490

5.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

Review 6.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

7.  Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract.

Authors:  Gail L Sturdevant; Harlan D Caldwell
Journal:  Pathog Dis       Date:  2014-04-10       Impact factor: 3.166

8.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  Plasmid-mediated transformation tropism of chlamydial biovars.

Authors:  Lihua Song; John H Carlson; Bing Zhou; Kimmo Virtaneva; William M Whitmire; Gail L Sturdevant; Stephen F Porcella; Grant McClarty; Harlan D Caldwell
Journal:  Pathog Dis       Date:  2013-11-11       Impact factor: 3.166

10.  Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection.

Authors:  Norma Olivares-Zavaleta; William Whitmire; Donald Gardner; Harlan D Caldwell
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.